1. Home
  2. FATN vs LCTX Comparison

FATN vs LCTX Comparison

Compare FATN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATN
  • LCTX
  • Stock Information
  • Founded
  • FATN 1989
  • LCTX 1990
  • Country
  • FATN United States
  • LCTX United States
  • Employees
  • FATN N/A
  • LCTX N/A
  • Industry
  • FATN
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FATN
  • LCTX Health Care
  • Exchange
  • FATN NYSE
  • LCTX Nasdaq
  • Market Cap
  • FATN 132.0M
  • LCTX 107.3M
  • IPO Year
  • FATN 2025
  • LCTX N/A
  • Fundamental
  • Price
  • FATN $8.66
  • LCTX $0.66
  • Analyst Decision
  • FATN
  • LCTX Strong Buy
  • Analyst Count
  • FATN 0
  • LCTX 5
  • Target Price
  • FATN N/A
  • LCTX $4.20
  • AVG Volume (30 Days)
  • FATN 111.3K
  • LCTX 1.0M
  • Earning Date
  • FATN 01-01-0001
  • LCTX 05-13-2025
  • Dividend Yield
  • FATN N/A
  • LCTX N/A
  • EPS Growth
  • FATN 56.77
  • LCTX N/A
  • EPS
  • FATN 0.37
  • LCTX N/A
  • Revenue
  • FATN $17,876,645.00
  • LCTX $9,557,000.00
  • Revenue This Year
  • FATN N/A
  • LCTX N/A
  • Revenue Next Year
  • FATN N/A
  • LCTX $232.66
  • P/E Ratio
  • FATN $24.38
  • LCTX N/A
  • Revenue Growth
  • FATN 13.17
  • LCTX 19.42
  • 52 Week Low
  • FATN $5.60
  • LCTX $0.37
  • 52 Week High
  • FATN $23.27
  • LCTX $1.15
  • Technical
  • Relative Strength Index (RSI)
  • FATN N/A
  • LCTX 65.30
  • Support Level
  • FATN N/A
  • LCTX $0.48
  • Resistance Level
  • FATN N/A
  • LCTX $0.70
  • Average True Range (ATR)
  • FATN 0.00
  • LCTX 0.05
  • MACD
  • FATN 0.00
  • LCTX 0.02
  • Stochastic Oscillator
  • FATN 0.00
  • LCTX 67.84

About FATN FATPIPE INC

Fatpipe Inc is a pioneer in enterprise-class, application-aware, secure SD-WAN solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and other middle-market companies. It is engaged in delivering principal enterprise-class networking software technology. The company is dedicated to continually improving the way organizations connect, ensuring their networks are secure, reliable, and supporting their continued success. Its commitment lies in empowering its customers with a seamless and dependable connectivity infrastructure that safeguards their critical data and fosters business continuity. Further, the company's goal is to ensure its customers have unparalleled insights into their network operations.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: